CaSR polymorphism Arg990Gly and response to calcimimetic agents in end-stage kidney disease patients with secondary hyperparathyroidism and in cell culture

Personalized Medicine

Volumn 5, Issue 2, 2008, Pages 109-116

  Rothe, Hansjörg ^a   Shapiro, Warren ^b   Sun, Wei Y ^b   Matalon, Albert ^c  

^a Klinikum Neumarkt   (Germany)

^b BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium sensing receptor; End stage kidney disease; Hyperparathyroidism; Polymorphisms; Transfected HEK 293 cells

Indexed keywords

ARGININE; CALCIUM SENSING RECEPTOR; CINACALCET; GLYCINE; PARATHYROID HORMONE;

ADULT; AGED; ALLELE; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG PROTEIN BINDING; EXON; GENETIC ASSOCIATION; HEMODIALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; PARATHYROID HORMONE BLOOD LEVEL; PHARMACOGENETICS; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 42549093163     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.2.109     Document Type: Article

References (27)

1. Tfelt-Hansen J, Brown EM: The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit. Rev. Clin. Lab. Sci. 42(1), 35-70 (2005).
2. Bai M: Structure and function of the extracellular calcium sensing receptor (review). Int. J. Mol. Med. 4, 115-125 (1999).
3. (2+)-sensing receptor. Am. J. Kidney Dis. 25, 506-513. 1995 (1994).
4. 0-sensing receptor. J. Biol. Chem. 271(32), 19537-19545 (1996).
5. Hu J, Mora S, Colussi G et al.: Autosomal dominant hypocalcemia caused by a novel mutation in the loop 2 region of the human calcium receptor extracellular domain. J. Bone Miner. Res. 17(8), 1461-1469 (2002).
6. Yun FH, Wong BY, Chase M et al.: Genetic variation at the calcium-sensing receptor (CaSR) locus: implications for clinical molecular diagnostics. Clin. Biochem. 40(8), 551-561 (2007).
7. Vezzoli G, Terranegra A, Arcidiacono T et al.: R990G polymorphism of calcium-sensing receptor does produce a gain-of-function and predispose to primary hypercalciuria. Kidney Int. 71(11), 1155-1162 (2007).
8. Yamauchi M, Sugimoto T, Yamaguchi T et al.: Association of polymorphic alleles of the calcium-sensing receptor gene with the clinical severity of primary hyperparathyroidism. Clin. Endocrinol. 55, 373-379 (2001).
9. Yano S, Sugimoto T, Kanzawa M et al.: Association of polymorphic alleles of the calcium-sensing receptor gene with parathyroid hormone secretion in haemodialysis patients. Nephron 85, 317-323 (2000).
10. Yokoyama K, Shingematsu T, Tsukada T et al.: Calcium-sensing receptor gene polymorphism affects the parathyroid response to moderate hypercalcemic suppression in patients with end-stage renal disease. Clin. Nephrol. 57, 131-135 (2002).
11. Vezzoli G, Tanini A, Ferrucci L et al.: Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. J. Am. Soc. Nephrol. 13(10), 2517-2523 (2002).
12. Wada M, Nagano N, Nemeth EF: The calcium receptor and calcimimetics. Curr. Opin. Nephrol. Hypertens. 8(4), 429-433 (1999).
13. Dong BJ: Cinacalcef: an oral calcimimetic agent for the management of hyperparathyroidism. Clin. Ther. 27(11), 1725-1751 (2005).
14. Herbert SC: Therapeutic use of calcimimetics. Annu. Rev. Med. 57, 349-364 (2006).
15. Block GA, Martin KJ, de Francisco AL et al.: Cinacalcet for secondary hyperparathyroidism in patients receiving haemodialysis. N. Engl. J. Med. 350(15). 1516-1525 (2004).
16. Lindberg JS, Culleton B, Wong G: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in haemodialysis and peritoneal dialysis: a randomized, double-blind multicenter study. J. Am. Soc. Nephrol. 16, 800-807 (2005).
17. Moe S, Chertow GM, Coburn JW: Achieving NFK-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 67, 760-771 (2005).
18. Goodman WG, Fadda GZ, Filkelstein FO: Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism (HPT). Proceedings of the 36th Annual Meeting of the American Society of Nephrology. San Diego, CA, USA, 12-17 November 2003 (SA-PO741).
19. Rothe HM, Shapiro WB, Sun WY, Chou SY: Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl. Pharmacogen. Genomics 15, 29-34 (2005).
20. Rothe HM, Terranegra A, Shapiro W et al.: Calcium-sensing receptor gene polymorphism Arg990Gly influences the response to calcimimetic agents both in end-stage kidney disease patients with secondary hyperparathyroidism and in cell culture. Poster presented at: Joint Cold Spring Harbor Laboratory/Wellcome Trust Conference on Pharmacogenomics. Hinxton, UK, 17-20 October 2007.
21. Miedlich S, Lamesch P, Mueller A, Paschke R: Frequency of the calcium-receptor variant A986S in patients with primary hyperparathyroidism. Eur. J. Endocrinol. 145, 421-427 (2001).
22. Gupta A, Kallenbach LR, Zasuwa G, Divine GW: Race is a major determinant of secondary hyperparathyroidism in uremic patients. J. Am. Soc. Nephrol. 11, 330-334 (2000).
23. de Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM: The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J. Am. Soc. Nephrol. 13, 2762-2769 (2002).
24. Canaff L: Extracellular calcium-sensing receptor is expressed in rat hepatocytes coupling to intracellular calcium mobilization and stimulation of bile flow. J. Biol. Chem. 276(6), 4070-4079 (2001).
25. Akiba T, Akizawa T, Uchida E, Tsukamoto Y, Koshikawa S; KRN 1493 Study Group: Randomized, double blind, placebo-controlled, dose-finding parallel study for KRN 1493 (cinacalcet HCl) in Japanese haemodialysis patients. J. Am. Soc. Nephrol. 16, A503 (2005).
26. Goodman WG, Hladik GA. Turner SA et al.: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. J. Am. Soc. Nephrol. 13, 1017-1024 (2002).
27. Pearce SHS, Bai M, Quinn SJ, Kifor O, Brown EM, Thakker RV: Functional characterization of calcium-sensing receptor mutations expressed in human embryonic kidney cells. J. Clin. Invest. 98, 1860-1866 (1996).